Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N07 OTHER NERVOUS SYSTEM DRUGS
N07X OTHER NERVOUS SYSTEM DRUGS
N07XX Other nervous system drugs
N07XX13 Valbenazine
D10999 Valbenazine tosylate (USAN) <JP/US>
USP drug classification [BR:br08302]
Central Nervous System Agents
Central Nervous System, Other
Valbenazine
D10999 Valbenazine tosylate (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
119 Miscellaneous
1190 Miscellaneous
D10999 Valbenazine tosylate (USAN); Valbenazine tosilate (JAN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG02115 Valbenazine
D10999 Valbenazine tosylate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG02115 Valbenazine
D10999 Valbenazine tosylate
DG02925 CYP3A5 substrate
DG02115 Valbenazine
D10999 Valbenazine tosylate
Target-based classification of drugs [BR:br08310]
Transporters
Solute carrier family
SLC18
SLC18A2 (VMAT2)
D10999 Valbenazine tosylate (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10999
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10999
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10999
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10999
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D10999
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG02115 Valbenazine
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG02115 Valbenazine
DG02925 CYP3A5 substrate
DG02115 Valbenazine